Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
Rhea-AI Summary
Femasys (NASDAQ: FEMY) expanded its European commercial footprint by signing a distribution agreement with OR Consulting to launch FemBloc permanent birth control, FemaSeed intratubal insemination, and other fertility and women’s diagnostic products in Switzerland. This follows recent market entry in Spain and ongoing launches in France as part of the company’s Europe expansion strategy.
Positive
- None.
Negative
- None.
News Market Reaction – FEMY
On the day this news was published, FEMY gained 1.43%, reflecting a mild positive market reaction. Argus tracked a peak move of +13.0% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $462K to the company's valuation, bringing the market cap to $33M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
FEMY was down 3.59% pre-news while peers showed mixed moves: EKSO up 10.24%, MHUA down 27.18%, BNGO down 3.79%, with others near flat. No clear, unified sector direction appears.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 14 | Nasdaq compliance update | Negative | +17.8% | Nasdaq grants 180-day extension to regain $1.00 minimum bid compliance. |
| Jan 13 | Commercial partnership | Positive | -1.5% | Refuah Health Center partnership to expand FemaSeed access in community care. |
| Dec 18 | Regulatory clearance | Positive | +4.1% | U.S. FDA 510(k) clearance for next‑generation FemVue diagnostic device. |
| Nov 14 | Earnings and financing | Positive | +8.6% | 3Q 2025 sales growth with new financing and multiple regulatory approvals. |
| Nov 10 | European order | Positive | +0.0% | Approx. $500,000 initial FemBloc order for France and Benelux expansion. |
Recent history shows mixed reactions: positive commercial and regulatory updates sometimes aligned with gains, but other constructive partnerships and compliance news have produced divergent or muted price moves.
Over the past few months, Femasys has combined regulatory, financing, and commercial milestones. An FDA 510(k) clearance for the next‑generation FemVue device on Dec 18, 2025 and a European FemBloc order on Nov 10, 2025 highlighted product and geographic expansion. Financing and 3Q 2025 results on Nov 14, 2025 strengthened liquidity. A Nasdaq bid‑price extension on Jan 14, 2026 and a U.S. FemaSeed partnership on Jan 13, 2026 underscored both listing risk and ongoing commercialization, providing context for today’s European distribution news.
Regulatory & Risk Context
The company has an active S-3 shelf registration filed on Jul 03, 2025, currently noted as not effective, with at least one related 424B3 usage on Jan 09, 2026 registering resale shares from prior financing.
Market Pulse Summary
This announcement adds to Femasys’ European strategy by securing a Swiss distribution partner for FemBloc, FemaSeed and other portfolio products, following earlier launches in Spain and France. It extends the commercial footprint without introducing new financial terms. In context of recent regulatory clearances, financings, and Nasdaq compliance efforts, investors may watch for concrete uptake indicators, such as follow-on orders or geographic expansions, and how these commercial steps interact with ongoing pivotal trial progress and capital structure disclosures.
Key Terms
intratubal insemination medical
AI-generated analysis. Not financial advice.
-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe --
ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent Birth Control, FemaSeed Intratubal Insemination, and additional Femasys fertility and women’s diagnostic health products. Together with the Company’s recent market entry in Spain and the ongoing commercial launch in France, this partnership represents continued execution of Femasys’ European expansion strategy and broadens access to its innovative technologies through experienced regional partners.
“Expanding into Switzerland with OR Consulting further strengthens our European commercial platform and reflects our disciplined approach to building a multi-country footprint through experienced regional partners,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “With FemBloc launches underway in Spain and France, and Switzerland providing access to our full portfolio, including FemaSeed for fertility, we are advancing availability across Europe while executing our long-term global growth strategy.”
“Switzerland is an important and sophisticated market for women’s health innovation,” said Christophe Sarzier, Chief Executive Officer of OR Consulting. “We are excited to support the introduction of FemBloc alongside Femasys’ broader fertility and women’s health solutions. Our collaboration reflects a shared commitment to working closely with physicians, navigating complex markets effectively, and expanding access to meaningful options for patients.”
About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1
FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
About OR Consulting
OR Consulting is a Switzerland-based medical technology consulting and distribution company with deep expertise in supporting innovative surgical and gynecologic solutions in both operating room and clinical settings. Founded and led by the same family behind Surgynal, OR Consulting draws on decades of experience in the development, commercialization, and clinical support of advanced urogynecologic and pelvic health technologies. Through this close affiliation, the company brings a strong foundation in physician education, in-procedure clinical support, and market development, and is recognized for its hands-on approach, close collaboration with healthcare providers, and commitment to introducing clinically differentiated technologies across Switzerland. More information on OR Consulting can be found at www.orconsulting.biz.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com
FAQ
What did Femasys (FEMY) announce about its Switzerland distribution agreement on February 3, 2026?
How does the OR Consulting partnership affect Femasys (FEMY) product availability in Europe?
Which Femasys (FEMY) products will OR Consulting distribute in Switzerland?
What is the strategic significance of Switzerland for Femasys (FEMY)?
Will the Femasys (FEMY) Switzerland deal change its ongoing launches in Spain and France?
How will the OR Consulting relationship support physician adoption of Femasys (FEMY) products in Switzerland?
